Navigation Links
GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
Date:5/16/2008

reating this complex form of breast cancer."

Despite receiving multiple prior lines of anti-cancer therapy, patients who received TYKERB plus trastuzumab in this study experienced:

-- A statistically significant increase in median progression-free survival

versus TYKERB alone (12 weeks vs. 8.1 weeks) (1)

-- A 27 percent reduction in the risk of disease progression [Hazard Ratio:

0.73; p=0.008] (1)

-- A response rate of 10.3 percent versus 6.9 percent. Response rate is a

clinical term that is calculated by complete and partial disappearance

of the tumor.

-- Double the overall clinical benefit rate versus TYKERB alone (24.7

percent vs. 12.4 percent; p=0.01) (1). Clinical benefit rate is

calculated by the response rate and the rate of durable stable disease

(greater than or equal to 6 months).

-- A trend in improved overall survival [Hazard Ratio: 0.75; p=0.106] (1)

The study also demonstrated the activity of TYKERB as a single agent in this patient population, with patients on this arm achieving a median progression free survival of 8.1 weeks and an overall clinical benefit rate of 12.4 percent (1).

The clinical synergy of TYKERB and trastuzumab confirms previous observational findings in preclinical studies and previously reported data from a Phase I study. These latest findings confirm the rationale for further research of this combination in earlier lines of therapy in the metastatic setting and in early stage disease. Additional analysis is underway to explore the benefit that TYKERB plus trastuzumab can offer to less heavily pre-treated patients (1).

Study Background

In this study, 296 patients with HER2 positive breast cancer who had documented progression on trastuzumab treatment in the metastatic setting were eligible to be randomized to receive TYKERB (1000 mg QD) plus trastuzumab (2 mg/kg weekly after 4 mg/kg lo
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
2. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
3. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
4. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
5. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
6. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
7. Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
8. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
11. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... HILDEN , Deutschland, und ... , ... ermöglicht QIAGEN die Entwicklung von ... Genpanels, für Blutkrebs  Neuer Test ... Patienten mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen ...
(Date:7/24/2014)... Ohio, July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... for 2014.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... , Net earnings per diluted share as reported ... quarter of 2013. Adjusted EPS was $2.57, an increase ...
(Date:7/24/2014)... 24, 2014 IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has accepted  ... Directors.  Mr. Finio has accepted a senior level finance ... of his acceptance of his new position, Mr. Finio ... Director for IGI Laboratories, Inc.  The effective date of ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 2Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 3Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 4Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 5Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 6Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 7Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 8Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 9Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 10Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 11Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 12Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 13Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 14Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 15Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 16Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 17Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 18Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 19Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 20Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 2Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 3Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 4Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 5Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 6Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 7Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 8
(Date:7/25/2014)... (PRWEB) July 25, 2014 Merrill ... of technology-enabled services for the financial, legal, healthcare ... virtual data room business, Merrill DataSite, has been ... presented by GrowthBusiness at the M&A Awards 2014 ... the achievements of entrepreneurs, management teams, advisors and ...
(Date:7/25/2014)... Ticket Down is a reliable source for ... at California Memorial Stadium. With the post-World Cup emotions ... organizers of the 2014 Guinness International Champions Cup have brought ... With teams representing La Liga, English Premier League, Serie A, ... best football players from around the world to 12 American ...
(Date:7/25/2014)... July 25, 2014(BRONX, NY)A study involving nearly 27,000 older ... 10 met criteria for pre-dementia based on a simple ... they have cognitive complaints. People who tested positive for ... dementia within 12 years. The study, led by scientists ... Yeshiva University and Montefiore Medical Center , was ...
(Date:7/25/2014)... As thousands of transvaginal mesh lawsuits ... Liebhard LLP notes that the Food & Drug Administration ... group, Public Citizen, to order a global recall of ... 1, 2014, and released to the public last week, ... ban on the marketing of all surgical mesh devices ...
(Date:7/25/2014)... drug can protect vulnerable neurons and reduce motor ... researchers at Emory University School of Medicine have ... Journal of Parkinson,s Disease . , The ... reach the brain at sufficient levels and have ... an insulin shot. Previous studies of XPro1595 in ...
Breaking Medicine News(10 mins):Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Slow walking speed and memory complaints can predict dementia 2Health News:Slow walking speed and memory complaints can predict dementia 3Health News:Slow walking speed and memory complaints can predict dementia 4Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 4Health News:Anti-inflammatory drug can prevent neuron loss in Parkinson's model 2
... in just one state, but a resurgence could occur, CDC ... As the H1N1 swine flu outbreak eases to a point ... health officials are still urging Americans to get their swine ... Week," Kathleen Sebelius, Secretary of the U.S. Department of Health ...
... , , , , MINNEAPOLIS, Jan. ... National Courage Award . Since 1980, Minnesota-based Courage ... an individual,s contributions to the health, welfare and rehabilitation of ... winners include: Max Cleland, Justin Dart Jr., Sen. Bob Dole, ...
... DHA boosted memory of Alzheimer,s patients in study , ... nutrients might help improve memory in Alzheimer,s patients by stimulating ... shows. , Uridine, choline and the omega-3 fatty acid DHA ... molecules that make up brain cell membranes, which form synapses. ...
... LAVAL, QC, Jan. 8 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: ... draw down of $1 million under its standby equity distribution (SEDA) ... Labopharm issued 482,165 of its common shares to YA at a ... (All currency figures are in Canadian dollars.) , In accordance with ...
... ... at 32nd annual San Antonio Breast Cancer Symposium , ... Los Angeles, CA (PRWEB) January ... announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension ...
... low level X-rays, , FRIDAY, Jan. 8 (HealthDay News) ... airline flight approaching Detroit, officials have announced plans to increase ... some travelers wondering about the health effects of these devices. ... expose passengers to excess levels of radiation? Experts say no. ...
Cached Medicine News:Health News:As Swine Flu Ebbs, Officials Stress Importance of Vaccine 2Health News:As Swine Flu Ebbs, Officials Stress Importance of Vaccine 3Health News:Courage Center Seeks Nominations for 2010 National Courage Award 2Health News:Labopharm settles $1 million draw down under standby equity distribution agreement 2Health News:Labopharm settles $1 million draw down under standby equity distribution agreement 3Health News:Abraxis Provides Overview Of ABRAXANE Study 2Health News:Abraxis Provides Overview Of ABRAXANE Study 3Health News:Airport Full Body Scanners Pose No Health Threat: Experts 2Health News:Airport Full Body Scanners Pose No Health Threat: Experts 3
... with a single lumen or dual lumen ... adapter., ,Trac-Wedge™ device, and patient label ... patient label. Dual swivel elbow kits do ... Steri-Cath® systems are latex-free. , ...
... Minimize Patient Trauma and Increase Staff Protection ... (10 Fr, 12 Fr, 14 Fr, 16 ... Suction Catheters with Contro-Vac Valves and DeLee ... potential for inflammation,during suctioning. Each catheter utilizes ...
Suction Catheter Mini Soft Kits without Solutions...
SAFE-T-VAC Suction Catheter Kits with Protective Sleeve...
Medicine Products: